The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|October 11, 2022
Rheumatoid Arthritis Quiz: Rheumatic Disease Report Card
Author(s)Ingrid Torjesen
How much do you know about the Rheumatic Disease Report Card and how it relates to your practice? Test your knowledge with this quiz.
Advertisement
What is the Rheumatic Disease Report Card?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement